Dr. Tae Han Kim

Dr. Tae Han Kim is the founding CEO of Samsung Biologics, a contract development and manufacturing organization (CDMO) that helps its clients develop and manufacture complex biomedicinesbio-medicines for patients who suffer from a wide range of diseases. WithDr. Kim has a chemical engineering doctoral degree from the University of Texas at Austin and a wealth of professional experience, Dr. Kim is uniquely qualified for this position.

Before getting started with Samsung Biologics, he worked in a number of Samsung divisions. Having been with the company since 1979, he's developed a reputation for his adept ability to grow and adapt with the times. As new research debuted and the biopharmaceutical industry evolved to fit emerging needs, he explored countless ways to bring the company up to speed.

After serving in Samsung Group's Strategic Planning Office and holding a senior leadership position at Samsung Total Petrochemicals, he gained a strong foothold in the industry. He successfully restructured the financial models of Samsung General Chemicals. He also developed an aromatics plant, naphtha cracking center, and polypropylene and styrene monomer production plants. By overseeing and leading these projects, he expanded his skills and carved out a growing role in the success of Samsung.

As the Samsung Biologics CEO, Dr. Kim created this division in the middle of a proverbial storm in biological manufacturing. At the time when his team entered the market, this economic sector was going through a number of major shifts. The worldwide manufacturing capacity was limited compared to the expected growth in the variety and demand for biologic drugs. To coordinate the production and timely delivery of medications, Samsung Biologics had to be ready with solutions.

When it comes to servicing clients, Dr. Kim has his eye on a few key priorities. Customer satisfaction, service, and compliance are all at the heart of Samsung Biologics, and these values align perfectly with Samsung's larger goal of focusing on quality first. He wants partners to benefit from Samsung’s innovation, flexibility, and execution excellence without sacrificing client and industry standards for quality and regulatory compliance.

To that end, Samsung Biologics has built a continual processing platform that reduces regulatory risk and increases production capacity. Setting higher standards for biopharmaceutical manufacturing begins with having modern facilities with advanced technologies. In addition to manufacturing, Samsung Biologics can perform cell-line development, analytical testing, and aseptic filling without clients having to worry about whether they're meeting all cGMP requirements.

The future of Samsung Biologics looks equally bright as Dr. Kim looks ahead. The goal is to build additional facilities and improve capabilities to meet the growing market demand. As additional medications are brought to the market, companies need to find ways to develop, scale up, and manufacture them rapidly without delay. Samsung Biologics is fully equipped to meet these needs, and Dr. Kim's team aims to open new doors to clients. Ultimately, this can allow the developers of new medications to accomplish more in less time. When the burden of regulatory compliance is removed with the help of the right manufacturer, it leads to better patient outcomes for all.

Before getting started with Samsung Biologics, he worked in a number of Samsung divisions beginning in 1979.

After serving in Samsung Group's Strategic Planning Office and holding a senior leadership position at Samsung Total Petrochemicals, he restructured the financial models of Samsung General Chemicals. He also developed an aromatics plant, naphtha cracking center, and polypropylene and styrene monomer production plants.

Dr. Tae Han Kim is the founding CEO of Samsung Biologics, a contract development and manufacturing organization (CDMO) that helps its clients develop and manufacture complex biomedicines for patients who suffer from a wide range of diseases. With a chemical engineering doctoral degree from the University of Texas at Austin and a wealth of professional experience, Dr. Kim is uniquely qualified for this position.

Before getting started with Samsung Biologics, he worked in a number of Samsung divisions. Having been with the company since 1979, he's developed a reputation for his adept ability to grow and adapt with the times. As new research debuted and the biopharmaceutical industry evolved to fit emerging needs, he explored countless ways to bring the company up to speed.

After serving in Samsung Group's Strategic Planning Office and holding a senior leadership position at Samsung Total Petrochemicals, he gained a strong foothold in the industry. He successfully restructured the financial models of Samsung General Chemicals. He also developed an aromatics plant, naphtha cracking center, and polypropylene and styrene monomer production plants. By overseeing and leading these projects, he expanded his skills and carved out a growing role in the success of Samsung.

As the Samsung Biologics CEO, Dr. Kim created this division in the middle of a proverbial storm in biological manufacturing. At the time when his team entered the market, this economic sector was going through a number of major shifts. The worldwide manufacturing capacity was limited compared to the expected growth in the variety and demand for biologic drugs. To coordinate the production and timely delivery of medications, Samsung Biologics had to be ready with solutions.

When it comes to servicing clients, Dr. Kim has his eye on a few key priorities. Customer satisfaction, service, and compliance are all at the heart of Samsung Biologics, and these values align perfectly with Samsung's larger goal of focusing on quality first. He wants partners to benefit from Samsung’s innovation, flexibility, and execution excellence without sacrificing client and industry standards for quality and regulatory compliance.

To that end, Samsung Biologics has built a continual processing platform that reduces regulatory risk and increases production capacity. Setting higher standards for biopharmaceutical manufacturing begins with having modern facilities with advanced technologies. In addition to manufacturing, Samsung Biologics can perform cell-line development, analytical testing, and aseptic filling without clients having to worry about whether they're meeting all cGMP requirements.

The future of Samsung Biologics looks equally bright as Dr. Kim looks ahead. The goal is to build additional facilities and improve capabilities to meet the growing market demand. As additional medications are brought to the market, companies need to find ways to develop, scale up, and manufacture them rapidly without delay. Samsung Biologics is fully equipped to meet these needs, and Dr. Kim's team aims to open new doors to clients. Ultimately, this can allow the developers of new medications to accomplish more in less time. When the burden of regulatory compliance is removed with the help of the right manufacturer, it leads to better patient outcomes for all.